Quantcast

Latest Organofluorides Stories

2014-06-23 23:05:46

Process for Filing Multidistrict Litigation Cases to be Streamlined as a Result ST. LOUIS, MO (PRWEB) June 23, 2014 The national law firm of Baron and Budd reports that the federal judge presiding over lawsuits involving the cholesterol drug Lipitor issued a Case Management Order on June 2, 2014. As a result, the process of filing new cases in the multidistrict litigation (MDL) will be streamlined. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502) In issuing the order, U.S. District...

2014-06-23 23:01:53

The Firm is representing a number of Risperdal lawsuit clients in claims that allege use of the antipsychotic medication caused men and boys to develop gynecomastia (male breast growth). New York, New York (PRWEB) June 23, 2014 Plaintiffs in Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) pending in a mass tort litigation in Pennsylvania’s Philadelphia Court of Common Pleas have responded to a defense motion seeking to have some Risperdal gynecomastia claims dismissed on...

2014-06-20 23:09:40

The San Diego personal injury lawyers of The Law Office of Melinda J. Helbock, A.P.C. are investigating potential lawsuits on behalf of boys and men who developed gynecomastia after using Risperdal. San Diego, California (PRWEB) June 20, 2014 According to a recent study, use of atypical antipsychotics in children is increasing in Australia and other countries. According to the study, more than 12,600 children under the age 19 are using antipsychotics, and the most commonly prescribed drug...

Tablet with a medicine
2014-06-19 10:33:25

Brett Smith for redOrbit.com - Your Universe Online In an attempt to raise awareness about a potential increased risk of suicide tied to antidepressant use, health officials may have made inadvertently made the problem worse. According to a new study in the British Medical Journal, FDA warnings about the increased risk of suicide and subsequent media coverage in 2003 were followed by a sudden drop in the number of prescriptions for antidepressants without compensation through increases...

2014-06-17 08:30:31

Takeda and Lundbeck Announce Results at American Society of Clinical Psychopharmacology Annual Meeting HOLLYWOOD, Fla., June 17, 2014 /PRNewswire/ -- Takeda Pharmaceuticals Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will present results about sexual functioning from a head-to-head study of Brintellix(®) (vortioxetine) vs. escitalopram in patients with well treated major depressive disorder (MDD) experiencing treatment-emergent sexual...

2014-06-16 08:27:34

Takeda and Lundbeck to Present Late-breaker at International College of Neuropsychopharmacology World Congress VANCOUVER, British Columbia, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated the effect of Brintellix 10-20 mg/d on aspects of cognitive function, using an objective neuropsychological test (the Digit Symbol Substitution Test or DSST) associated with executive...

2014-06-15 23:01:05

The Firm is actively filing Risperdal lawsuits on behalf of men and young boys who allegedly developed gynecomastia, a condition categorized by male breast growth, after use of the antipsychotic. New York, NY (PRWEB) June 15, 2014 A consolidated litigation involving Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) is continuing to move forward in Pennsylvania state court, where an upcoming status conference is scheduled to take place next month, Bernstein Liebhard LLP reports....

2014-06-11 23:02:08

The Firm is representing numerous boys and men in Risperdal lawsuits that allege use of the antipsychotic drug caused gynecomastia, or male breast growth. New York, New York (PRWEB) June 11, 2014 Janssen Pharmaceuticals, a division of Johnson & Johnson and a defendant in hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) pending in a Pennsylvania mass tort proceeding, is attempting to block a bid by plaintiffs to revive punitive damage claims in cases that allege...

2014-06-10 23:16:02

Avail is conducting a phase 1, open-label pharmacokinetic and pharmacodynamic study of a single dose of an experimental drug in subjects with hepatic impairment and in matched healthy volunteers. DeLand, FL (PRWEB) June 10, 2014 To see if you qualify for this Hepatic Impairment Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no insurance is required, and you may...

2014-06-10 12:30:30

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insighthttp://www.reportbuyer.com/pharma_healthcare/diseases/non_small_cell_lung_cancer_game_changing_immunotherapies_revolutionise_treatment_kol_insight.html Change is coming to the NSCLC treatment algorithm--and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related